Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ: NTLA )

10.70 +1.06 (+11.00%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Preview: Intellia Therapeutics's Earnings
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
These three undervalued biotech stocks could have plenty of room to run if their efforts to push out promising pipeline drugs are successful. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
These are the three bargain biotech stocks showcasing massive upside potential for investors looking to find a position in the sector. 
Via InvestorPlace
3 Pharma Stocks That AI is Loving in July
Artificial intelligence recommends that these are the three stocks to consider when investing in pharma stocks. 
Via InvestorPlace
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
1 Cathie Wood Stock That Could Double Your Money
This gene-editing pioneer stands out as a top growth stock to buy right now. 
Via The Motley Fool
What 10 Analyst Ratings Have To Say About Intellia Therapeutics
Via Benzinga
Where Intellia Therapeutics Stands With Analysts
Via Benzinga
Why Is Intellia (NTLA) Stock Up 5% Today?
NTLA stock is trending on social media and is up over 5%. The drugmaker reported new, positive results from its gene-edited treatment. 
Via InvestorPlace
What Will Amgen Buy Next?
The biotech could pursue these two budget-friendly targets. 
Via The Motley Fool
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
Reaching profitability could be harder than investors expect. 
Via The Motley Fool
What Is CRISPR And Why Should Your Portfolio Care?
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player. 
Via Talk Markets
3 Monster Stocks in the Making to Buy Right Now
They're not monsters now -- but just give them some time. 
Via The Motley Fool
Wall Street Expects Intellia Therapeutics Stock to Climb 107%. Is That Too Optimistic?
Pre-revenue biotechs don't have many ways to juice their share prices. 
Via The Motley Fool
Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit?
There's more than one reason to sell a stock while buying another. 
Via The Motley Fool
Can This Gene-Editing Stock Deliver 10X Returns?
Buying shares of Intellia Therapeutics might be a smart move. 
Via The Motley Fool
Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money.
One of these stocks has already doubled this year. 
Via The Motley Fool
Intellia Therapeutics Stock Could Roar in the Next Bull Market. Here's Why.
It has quite a few of the core ingredients for success in biopharma. 
Via The Motley Fool
Here's the Secret Behind Cathie Wood's Latest Moneymaking Strategy
Success could be in the DNA of the Ark Invest founder. 
Via The Motley Fool
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
3 Cathie Wood Investments That Could Deliver Superior Returns
These three stocks fit Wood's profile for big-time growth. 
Via The Motley Fool
2 Short-Squeeze Candidates That Could Go Parabolic
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately. 
Via The Motley Fool
2 Growth Stocks Cathie Wood Is Buying Hand Over Fist
The fund manager most famous for innovation-focused investing thinks these two stocks have what it takes to produce big gains. 
Via The Motley Fool
Hereditary Angioedema Update Solidifies Intellia's Cell Therapy's Competitive Efficacy Profile: Analyst
Sunday, Intellia Therapeutics Inc (NASDAQ: NTLA) announced updated interim results from the Phase 1 portion of the ongoing  
Via Benzinga
Why Are Cruise Stocks CCL, RCL, NCLH Up Today?
Cruise stocks are on the rise Monday as investors react to a positive note to clients from JPMorgan analysts and we've got the details! 
Via InvestorPlace
BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing
Biogen (BIIB) stock is a hot topic among traders Monday as the company's share resumed trading following a halt that was in effect on Friday. 
Via InvestorPlace
Intellia Therapeutics Surges As CRISPR Gene-Editing Drug Potentially Cures Swelling Disease
The company is testing a treatment for hereditary angioedemia, a potentially fatal swelling disorder. 
Via Investor's Business Daily
Why Intellia Therapeutics Stock Is Rising Monday
Intellia Therapeutics Inc (NASDAQ: NTLA) shares are trading higher Monday after the clinical-stage genome editing company announced data for its treatment for people living with hereditary angioedema... 
Via Benzinga
Chinook Therapeutics, Oracle And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. Chinook Therapeutics, Inc. (NASDAQ: KDNY) shares jumped 66.8% to $40.01 in... 
Via Benzinga
Wall Street Says These 2 Stocks May Double. Should You Buy Them?
Both of these stocks have declined over the past year. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.